Global Diagnostics San Diego based Genlantis Diagnostics develops rapid self-test diagnostic kits for HBV, HCV, HIV, Dengue, Chikungunya, and Zika, indicating opportunities to cross-sell or bundle infectious disease testing solutions to global markets and public health programs.

Small Team, Agility With a lean workforce (2-10 employees) and revenue in the 1-10 million range, there is potential for high-touch outbound selling, partner-led distribution, and scalable channel strategies to accelerate growth.

Tech Stack Leverage Reliance on cloud infrastructure (Google Cloud), modern web technologies, and HTTP/3 readiness suggests ease of integration for companion software, data capture, and digital platforms to support test results, telemetry, and developer-friendly partnerships.

Emerging Markets Product focus on several high-priority infectious diseases with global relevance positions the company to target regions with rising demand for rapid diagnostics, including areas affected by dengue, Zika, and hepatitis or HIV testing campaigns.

Competitive Positioning In a landscape with large incumbents, emphasize nimble development, potential for rapid product iterations, and differentiators around rapid self-tests and point-of-care diagnostics to win partnerships with bigger players or distributors seeking specialized kits.